Literature DB >> 7092289

Defective yeast opsonisation and functional deficiency of complement in sickle cell disease.

V F Larcher, R J Wyke, L R Davis, C E Stroud, R Williams.   

Abstract

Opsonisation of heat-killed baker's yeast, functional activity of the total alternative pathway of complement, and factor B detected functionally and immunochemically were significantly reduced in 72 children with sickle cell disease compared with 40 age-matched black control children. There was significant correlation between functional activity of the total alternative pathway and functionally measured factor B, but not between factor B measured functionally and immunochemically. The opsonisation defect could be corrected in vitro by normal serum, and factor B-depleted serum, and was qualitatively similar to that seen in patients with primary yeast opsonisation deficiency. Serial studies showed that these serum defects were persistent. Reduction in the activity of components of the alternative pathway of complement and opsonisation was found in 4 patients who had recovered from pneumococcal meningitis and in one who developed osteomyelitis. Defects of yeast opsonisation and complement which are common in patients with sickle cell disease, may partly explain the children's increased susceptibility to infection, and might help to identify individuals especially at risk.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7092289      PMCID: PMC1627548          DOI: 10.1136/adc.57.5.343

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  16 in total

1.  Deficiency of factor B of the complement system in sickle cell anaemia.

Authors:  W A Wilson; G R Hughes; P J Lachmann
Journal:  Br Med J       Date:  1976-02-14

2.  A defect of the alternative pathway of complement.

Authors:  J F Soothill; B A Harvey
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

3.  Diplococcus pneumoniae infections in children with sickle cell anemia.

Authors:  R A Seeler; W Metzger; M A Mufson
Journal:  Am J Dis Child       Date:  1972-01

4.  The liver in sickle cell anemia. A clinical-pathologic study.

Authors:  H J Rosenblate; R Eisenstein; A W Holmes
Journal:  Arch Pathol       Date:  1970-09

5.  Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation.

Authors:  A Martin; P J Lachmann; L Halbwachs; M J Hobart
Journal:  Immunochemistry       Date:  1976-04

6.  Alternative complement pathway activity in sera from patients with sickle cell disease.

Authors:  S M Koethe; J T Casper; G E Rodey
Journal:  Clin Exp Immunol       Date:  1976-01       Impact factor: 4.330

7.  An abnormality of the alternate pathway of complement activation in sickle-cell disease.

Authors:  R B Johnston; S L Newman; A G Struth
Journal:  N Engl J Med       Date:  1973-04-19       Impact factor: 91.245

8.  Decreased opsonization for Streptococcus pneumoniae in sickle cell disease: studies on selected complement components and immunoglobulins.

Authors:  A B Bjornson; M H Gaston; C L Zellner
Journal:  J Pediatr       Date:  1977-09       Impact factor: 4.406

9.  Defective opsonization. A common immunity deficiency.

Authors:  J F Soothill; B A Harvey
Journal:  Arch Dis Child       Date:  1976-02       Impact factor: 3.791

10.  Activation of the alternate complement pathway by autologous red cell stroma.

Authors:  T R Poskitt; H P Fortwengler; B J Lunskis
Journal:  J Exp Med       Date:  1973-09-01       Impact factor: 14.307

View more
  7 in total

1.  Nature of complement deficiency in sickle cell disease.

Authors:  W A Wilson
Journal:  Arch Dis Child       Date:  1983-03       Impact factor: 3.791

Review 2.  Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses.

Authors:  Emmanuel Balandya; Teri Reynolds; Stephen Obaro; Julie Makani
Journal:  Am J Hematol       Date:  2016-07-14       Impact factor: 10.047

3.  Serum opsonic activity in infants with sickle-cell disease immunized with pneumococcal polysaccharide protein conjugate vaccine. The Pneumococcal Conjugate Vaccine Study Group.

Authors:  A Nowak-Wegrzyn; J A Winkelstein; A J Swift; H M Lederman
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

4.  Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019.

Authors:  Marianne E Yee; Kristina W Lai; Nitya Bakshi; Joanna K Grossman; Preeti Jaggi; Alexander Mallis; Yun F Wang; Robert C Jerris; Peter A Lane; Inci Yildirim
Journal:  Pediatrics       Date:  2022-01-01       Impact factor: 7.124

5.  Sepsis caused by Mycobacterium terrae complex in a patient with sickle cell disease.

Authors:  Ashwini K Esnakula; Sudhir K Mummidi; Patricia A Oneal; Tammey J Naab
Journal:  BMJ Case Rep       Date:  2013-05-02

Review 6.  Complement in Sickle Cell Disease: Are We Ready for Prime Time?

Authors:  Eleni Gavriilaki; Efthymia Vlachaki; Christos Varelas; Athina Tampaki; Ioanna Sakellari; Αchilles Anagnostopoulos
Journal:  J Blood Med       Date:  2021-03-23

7.  Effects of vaccines in patients with sickle cell disease: a systematic review protocol.

Authors:  Alison Beriliy Wiyeh; Leila Hussein Abdullahi; Ambroise Wonkam; Charles Shey Wiysonge; Mamadou Kaba
Journal:  BMJ Open       Date:  2018-03-25       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.